MAZE - NASDAQ
Maze Therapeutics, Inc.
$25.06
+3.2%Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
At a Glance
Live SnapshotMaze Therapeutics, Inc. Management Team
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
Chief Executive Officer & Director
Compensation
$812,262
Mr. Atul Dandekar
Chief Strategy & Business Officer
Ms. Courtney J. Phillips J.D.
General Counsel & Corporate Secretary
Compensation
$354,780
Dr. Harold S. Bernstein M.D., Ph.D.
President of Research & Development and Chief Medical Officer
Compensation
$764,167
Mr. Winston Tse
Senior Vice President of Drug Discovery
Ms. Amy Bachrodt
Senior Vice President of Finance & Chief Financial Officer
Mr. Matt Krause
Senior Vice President of Human Resources
Mr. Maarten Hoek
Senior Vice President of Research
Ms. Nazila Habibizad
Senior Vice President of Technical Operations & Supply Chain
Mr. Vipin Vijayakumar
Vice President of R&D Infrastructure and Operations
Maze Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $991K and sold $9.45M worth of MAZE shares, resulting in $8.46M of net selling activity.
3 Months
0
0.00
100.8K
3.54M
-3.5M
-$3.54M
3-6 Months
0
0.00
135.0K
5.44M
-5.4M
-$5.44M
6-9 Months
36.0K
990.72K
20.7K
464.03K
+527K
+$527K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Hoppenot Herve
Director
$991K
Top Sellers
Bernstein Harold
Officer: President, R&D & Cmo
$3.36M
Dandekar Atul
Officer: Csbo
$3.32M
Sohn Catherine A.
Director
$1.15M
Coloma Jason V
Director, Officer: Chief Executive Officer
$830K
Scheller Richard H
Director
$464K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $8.46M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
MAZE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 08, 2026 | 2026 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.